Patents Assigned to VACDIAGN BIOTECHNOLOGY CO., LTD.
  • Patent number: 11352411
    Abstract: Disclosed are a fusion peptide of CD4 helper T cell epitopes, a nucleic acid encoding the same and an immunogenic composition comprising the same. The epitope fusion peptide comprises a cytomegalovirus epitope and an influenza virus epitope. The epitope fusion peptide can substantially improve the level of cellular immune response to a target immunogen, particularly a weak immunogen, and is an effective means for overcoming the immune tolerance of immune system to an antigen, particularly to a tumor antigen or an infection-related antigen, and is suitable for efficiently enhancing the efficacy of vaccine.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: June 7, 2022
    Assignee: Vacdiagn Biotechnology Co., Ltd
    Inventors: Jianqing Xu, Yang Huang, Xiaoyan Zhang
  • Publication number: 20220002750
    Abstract: The present invention provides a recombinant viral vector, an immunogenic composition containing the same, and the use thereof. The recombinant viral vector comprises a polynucleotide encoding a fusion peptide of CD4 helper T cell epitopes, the epitope fusion peptide comprising a cytomegalovirus epitope and/or an influenza virus epitope. The epitope fusion peptide and the recombinant viral vector provided by the present invention can improve the level of cellular immune response to a target immunogen, particularly to a weak immunogen, and overcome the immune tolerance of immune system to an antigen, particularly to a tumor antigen or an infection-related antigen. The products of the present invention are suitable for enhancing the efficacy of vaccines.
    Type: Application
    Filed: June 12, 2019
    Publication date: January 6, 2022
    Applicant: VACDIAGN BIOTECHNOLOGY CO., LTD
    Inventors: Jianqing Xu, Yang Huang, Xiaoyan Zhang, Lu Wang, Mingquan Gao, Jiahao Sun
  • Publication number: 20200216516
    Abstract: Disclosed are a fusion peptide of CD4 helper T cell epitopes, a nucleic acid encoding the same and an immunogenic composition comprising the same. The epitope fusion peptide comprises a cytomegalovirus epitope and an influenza virus epitope. The epitope fusion peptide can substantially improve the level of cellular immune response to a target immunogen, particularly a weak immunogen, and is an effective means for overcoming the immune tolerance of immune system to an antigen, particularly to a tumor antigen or an infection-related antigen, and is suitable for efficiently enhancing the efficacy of vaccine.
    Type: Application
    Filed: September 28, 2018
    Publication date: July 9, 2020
    Applicant: VACDIAGN BIOTECHNOLOGY CO., LTD
    Inventors: Jianqing Xu, Yang Huang, Xiaoyan Zhang
  • Patent number: 9504741
    Abstract: The invention provides a method of preventing the spreading of influenza viruses, and the factors making up the said method, and especially provides one type of combinatorial vaccine and the immunization method thereof. Two of more influenza vaccines are inoculated by a certain sequence, and each influenza vaccine vaccines is inoculated at least once, and the inoculation take place two or more times; wherein each influenza vaccine includes one or more antigens, the immunogenic fragments thereof, or the coding genes thereof, and further includes a different antigen, the immunogenic fragments or the coding gene of the different antigen.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: November 29, 2016
    Assignee: Vacdiagn Biotechnology Co., Ltd.
    Inventors: Jianqing Xu, Yang Huang
  • Publication number: 20140286993
    Abstract: The invention provides a method of preventing the spreading of influenza viruses, and the factors making up the said method, and especially provides one type of combinatorial vaccine and the immunization method thereof. Two of more influenza vaccines are inoculated by a certain sequence, and each influenza vaccine vaccines is inoculated at least once, and the inoculation take place two or more times; wherein each influenza vaccine includes one or more antigens, the immunogenic fragments thereof, or the coding genes thereof, and further includes a different antigen, the immunogenic fragments or the coding gene of the different antigen.
    Type: Application
    Filed: November 23, 2011
    Publication date: September 25, 2014
    Applicant: VACDIAGN BIOTECHNOLOGY CO., LTD.
    Inventors: Jianqing Xu, Yang Huang